1104TiP - Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 study

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Immunotherapy
Presenter Hardev Pandha
Citation Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378
Authors H.S. Pandha1, K. Harrington2, C. Ralph3, A. Melcher4, E. Schmidt5, D.R. Kaufman6, M. Grose7, R. Karpathy7, D. Shafren7
  • 1Oncology, University of Surrey, GU2 7WG - Surrey/GB
  • 2Division Of Radiotherapy And Imaging, The Institute of Cancer Research and Royal Marsden Hospital, SW7 6JB - London/GB
  • 3St. James's Institute Of Oncology, University of Leeds, Leeds/GB
  • 4Oncology And Clinical Research, Leeds Institute of Cancer and Pathology, Leeds/GB
  • 5Clinical, Merck Co, Kenilworth/US
  • 6Oncology Clinical Research, Merck & Co., Inc., Kenilworth/US
  • 7Viralytics, Viralytics Limited, Sydney/AU



CAVATAKTM is a novel, bio-selected ICAM-1-targeted immunotherapeutic Coxsackievirus A21 (CVA21). Infection of the tumour micro-environment by CVA21 can increase levels of immune-checkpoint molecules, immune-cell infiltration and enhancement of systemic antitumour immune response. Pembrolizumab is a human programmed death receptor-1 (PD-1) blocking antibody that has induced responses in a number of tumour types via reversal of tumour-induced T-cell suppression. Preclinical studies in immune-competent mouse models of NSCLC and melanoma suggest combinations of IV CVA21 + anti-PD-1 mAbs mediate greater antitumour activity compared to single agent use. As such, we propose that the combination of CVA21 + pembrolizumab may translate to similar benefits in the clinic. The KEYNOTE 200 Phase Ib study (NCT02043665) assesses tolerance and efficacy of IV-delivered CVA21 ± pembrolizumab in advanced cancer pts.

Trial design

Primary objectives are to assess dose-limiting toxicities (DLT) of CVA21 ± pembrolizumab. Secondary objectives include ORR by irRECIST criteria, PFS, and OS. Treatment: Part A: Pts are infused with CVA21 in Cohort 1 (n = 3), at a dose of 1 x 108 TCID50, in Cohort 2 (n = 3) at a dose of 3 x 108 TCID50 and in Cohort 3 (n = 12-18) at a dose of 1 x 109 TCID50 on study days 1,3,5,22 and Q3W for 6 additional infusions. Part A enrollment is almost complete. Part B: Pts are infused with CVA21 + pembrolizumab. In Cohort 1 (n = 3), CVA21 is administered at a dose of 1 x 108 TCID50, in Cohort 2 (n = 3) at a dose of 3 x 108 TCID50 and in Cohort 3 (n = ∼80) at a dose of 1 x 109 TCID50 on study days 1,3,5,8,29,and Q3W for 6 additional infusions. All subjects receive pembrolizumab at 200 mg IV Q3W from Day 8 for up to 2 years. Treatment with IV CVA21 ± pembrolizumab will continue until confirmed CR or PD (whichever comes first) per irRECIST or DLT. Key eligibility: Pts with advanced disease, lesion(s) accessible for core biopsy, ECOG PS 0-1, no active cerebral metastases, no autoimmunity/immunosuppression.

Clinical trial identification


Legal entity responsible for the study

Viralytics Limited


Viralytics Limited


H.S. Pandha: Research Funding - Viralytics Limited Travel, Accommodations, Expenses – Viralytics. K. Harrington: Honoraria - Amgen; Celgene; Merck Sharp & Dohme; Oncos Therapeutics Consulting - Amgen; Merck Sharp & Dohme; Viralytics (Inst). Research Funding - AstraZeneca; Genelux Oncolytics Biotech, Viralytics Travel - Boehringer Ingelheim, Viralytics. C. Ralph: Travel, Accommodations, Expenses – Viralytics. A. Melcher: Research Funding - Oncolytics Biotech, Viralytics Limited Travel, Accommodations, Expenses – Viralytics. E. Schmidt, D.R. Kaufman: Employment: Merck & Co. M. Grose, R. Karpathy, D. Shafren: Viralytics stock and employment.